NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

• Market Cap: $2.77B
• Dividend Yield: N/A
• Average Volume (3M): 803.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 68
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 112,628,456
• 10 Day Avg. Volume: 764,092
• 30 Day Avg. Volume: 803,917
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 29.87
• Enterprise Value/Gross Profit: 29.87
• Enterprise Value/Ebitda: -5.51
• 1Y Price Target: $41.24
• Price Target Upside: 65.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 61 Neutral
• Price Target: $25.00 ▲(0.48% Upside)

NewAmsterdam Pharma's overall score is driven by strong corporate events and technical analysis, offset by financial performance challenges and high-risk valuation. The company's strategic progress in clinical trials and regulatory achievements are promising, but profitability remains a key concern.

Positive Factors

Alzheimer's Disease Potential

Obi leads to statistically significant and clinically meaningful reductions in p-tau217, a biomarker associated with Alzheimer's disease.

Market Opportunity

The company maintained a solid cash position of ~$783M, which will amply support operations through key value-creating milestones, including the PREVAIL CV outcomes trial top-line readout and planned obi US launch preparations.

Product Differentiation

Obicetrapib (obi) represents a potentially transformative oral therapy for cardiovascular disease with a differentiated profile that addresses substantial unmet needs in LDL-C patient management.

Negative Factors

Commercialization Challenges

The choice of MACE-4 provides more CV events to attain the primary endpoint and would support a broader label to support commercialization, but it may come with higher expectations.

Investor Concerns

The lack of numerical data in Merck’s press release could lead some investors to assume the results are not as strong as the previous Phase II trials.

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company Description

NewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies to address cardiovascular diseases. The company operates within the biopharmaceutical sector, leveraging advanced scientific research to create novel treatments. Its core products include investigational therapies aimed at managing and preventing cardiovascular conditions, with a primary focus on dyslipidemia and other metabolic disorders.

How the Company Makes Money

NAMS primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around successful clinical trials that lead to regulatory approval, allowing it to either license its therapies to larger pharmaceutical companies or directly market them. Key revenue streams include milestone payments from licensing agreements, potential royalty payments from commercialized products, and partnerships with other pharmaceutical companies for co-development and co-marketing efforts. These partnerships provide significant financial support and shared resources, contributing to the company's earnings as it advances its product pipeline.

NewAmsterdam Pharma Company Financial Statement Overview

Summary

NewAmsterdam Pharma exhibits typical characteristics of a biotech firm with high R&D expenses leading to operational losses. While revenue growth is promising, profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity. The company must focus on achieving profitability to ensure long-term sustainability.

Income Statement

The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.

Cash Flow

Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.14M	45.56M	12.76M	95.91M	0.00	0.00
Gross Profit	47.14M	45.56M	12.76M	95.91M	0.00	0.00
EBITDA	-255.78M	-241.49M	-176.86M	-3.31M	-30.73M	-5.43M
Net Income	-187.36M	-241.60M	-176.94M	-21.14M	-36.71M	-5.75M
Balance Sheet
Total Assets	818.41M	864.62M	347.10M	531.58M	59.78M	9.23M
Cash, Cash Equivalents and Short-Term Investments	808.48M	834.19M	340.45M	438.52M	53.09M	7.86M
Total Debt	389.00K	448.00K	60.00K	118.00K	164.00K	11.65M
Total Liabilities	41.05M	107.12M	58.70M	47.06M	9.99M	12.81M
Stockholders Equity	777.36M	757.50M	288.39M	484.52M	49.79M	-3.58M
Cash Flow
Free Cash Flow	-86.55M	-159.24M	-141.24M	7.96M	-25.18M	-5.98M
Operating Cash Flow	-136.75M	-158.56M	-141.22M	7.97M	-25.16M	-5.97M
Investing Cash Flow	-59.40M	-62.85M	-24.00K	715.00K	-20.00K	-13.00K
Financing Cash Flow	467.53M	659.51M	8.91M	375.18M	68.99M	11.32M

NewAmsterdam Pharma Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 24.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Positive. The current price of 24.88 is above the 20-day moving average (MA) of 24.74, above the 50-day MA of 22.67, and above the 200-day MA of 21.32, indicating a bullish trend. The MACD of 0.59 indicates Positive momentum. The RSI at 61.44 is Neutral, neither overbought nor oversold. The STOCH value of 68.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAMS.

NewAmsterdam Pharma Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	78 Outperform	$2.13B	12.10	27.58%	―	17.74%	59.96%
NAMS	61 Neutral	$2.77B	―	-28.43%	―	―	―
ARQT	58 Neutral	$1.84B	―	-57.33%	―	99.50%	65.91%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
RXRX	50 Neutral	$2.03B	―	-86.34%	―	30.14%	-10.08%
DNLI	45 Neutral	$2.26B	―	-39.69%	―	-100.00%	1.62%
MTSR	40 Underperform	$3.80B	―		―	―	―

NewAmsterdam Pharma Company Corporate Events

NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials

On September 2, 2025, NewAmsterdam Pharma Company released an updated corporate investor presentation highlighting significant progress in its clinical trials for obicetrapib, a promising treatment for lowering LDL-C levels. The presentation detailed the company’s strategic plans, including securing funding for a potential U.S. commercial launch and expanding its workforce. The company’s trials have shown favorable results, indicating a substantial market opportunity, particularly in the U.S., where many patients are not meeting cholesterol goals with existing treatments.

NewAmsterdam Pharma’s EMA Validation for Obicetrapib

On August 18, 2025, NewAmsterdam Pharma announced that the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, both as a monotherapy and in combination with ezetimibe, for treating primary hypercholesterolemia and mixed dyslipidemia. This validation marks a significant step for NewAmsterdam, allowing the EMA to review pivotal Phase 3 trials, which demonstrated substantial LDL-C reductions. The company, in partnership with Menarini, aims to bring this novel treatment to Europe, potentially offering a new therapeutic option for patients not meeting LDL-C goals despite existing treatments.

NewAmsterdam Pharma Signs Supply Agreement with Menarini

On August 12, 2025, NewAmsterdam Pharma’s subsidiary entered into a Supply Agreement with A. Menarini International Licensing S.A. to supply obicetrapib monotherapy and combination drug products. The agreement outlines NewAmsterdam Pharma as the exclusive supplier initially, with plans to transfer manufacturing to Menarini or a third party, impacting the company’s operational dynamics and industry positioning.

NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results

On July 30, 2025, NewAmsterdam Pharma announced promising results from its Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s disease biomarkers. The trial showed that obicetrapib significantly reduced levels of plasma p-tau217, a key biomarker of Alzheimer’s pathology, especially in ApoE4 carriers, a group at heightened risk for the disease. These findings suggest that obicetrapib could offer a novel approach to Alzheimer’s prevention while also providing cardiovascular benefits, positioning the company as a potential leader in addressing both neurodegenerative and cardiovascular diseases.

NewAmsterdam Pharma Updates Employment Agreement with Executive

On July 11, 2025, NewAmsterdam Pharma B.V. updated its Employment Agreement with Dr. John Kastelein, effective July 1, 2025. This agreement outlines severance and benefits for Dr. Kastelein in cases of employment termination without cause or due to a change in control, impacting his stock options and equity awards.

NewAmsterdam Pharma Schedules R&D Day for June 2025

NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.

NewAmsterdam Pharma Announces Positive Phase 3 Trial Results

On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.

NewAmsterdam Pharma Approves Key Proposals at AGM

On June 4, 2025, NewAmsterdam Pharma Company N.V. held its annual general meeting where 74.45% of eligible shares voted. Shareholders approved several proposals, including the adoption of the 2024 annual accounts, discharge of directors’ liabilities, appointment of Deloitte as auditor, and various board appointments. The company also decided to hold annual Say-on-Pay votes until 2031.